文献速递慢性肾脏病

按尿白蛋白肌酐比分类预测CKD进展的人群负担

Projecting the Population Level Burden of CKD Progression According to Urine Albumin-to-Creatinine Ratio Categories.
PubMed 文献 · Kidney Int Rep · 2024-10-10

该研究利用Inside CKD微观模拟模型,基于人口学、流行病学和经济数据,在31个国家和地区人群中按KDIGO尿白蛋白肌酐比(uACR)A1-A3分类估算CKD的临床与经济负担。结果显示,2022年CKD G3-G5人群主要位于A1和A2分类,2022至2027年疾病进展和心肾并发症的累积发病率也主要发生在A1和A2分类,且这两个分类承担了大部分CKD管理和心肾并发症的医疗费用。研究提示A1和A2分类虽白蛋白尿轻度至中度升高,却构成CKD人群的绝大部分,应成为资源分配和干预的重点。

要点

  • CKD G3-G5人群在2022年主要分布于uACR A1和A2分类。
  • 2022至2027年CKD进展和心肾并发症主要发生在A1和A2分类。
  • A1和A2分类承担了大部分CKD相关医疗费用,应优先配置资源。

核心结论

  • KDIGO uACR A1和A2分类人群虽白蛋白尿轻度至中度升高,却承担了不成比例的人群层面临床和经济负担。
  • 提示医疗决策者应将资源与干预措施覆盖至A1和A2分类的CKD人群以降低整体负担。

研究设计与样本

  • Inside CKD模型为个体患者层面微观模拟,基于人口学、流行病学和经济数据模拟国家人群。
  • 分析覆盖31个国家和地区,按KDIGO uACR分类(A1-A3)估算人群层面临床与经济结局。

主要发现

  • 2022年CKD G3-G5人群(含诊断与未诊断个体)主要位于uACR A1和A2分类。
  • 2022至2027年CKD分期转换(疾病进展)和心肾并发症(心力衰竭、心肌梗死、卒中及全因死亡)的累积发病率主要发生在A1和A2分类。
  • A1和A2分类患者占CKD人群最大比例,在诊断人群中承担了大部分CKD管理和心肾并发症相关医疗费用(2027年患病率口径)。

临床怎么用

  • 在人群健康管理和资源配置中,不应仅关注白蛋白尿重度升高(A3)人群,A1和A2分类也应纳入重点干预范围。
  • 对白蛋白尿轻度至中度升高的CKD患者,早期识别和管理可能有助于降低心肾并发症和医疗费用负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Urinary albumin-to-creatinine ratio (uACR) is an independent predictor of chronic kidney disease (CKD) progression. However there is limited evidence on the burden of CKD according to uACR categories at the population level. This study estimates future clinical and financial burden of CKD according to uACR categories using the Inside CKD microsimulation. METHODS: The Inside CKD model is an individual patient level microsimulation that emulates national populations based on demographic, epidemiological, and economic data. The analysis estimates clinical and economic outcomes over time according to the Kidney Disease: Improving Global Outcomes (KDIGO) uACR categories (A1-A3) at a population level for 31 countries and regions. RESULTS: CKD populations (diagnosed and undiagnosed individuals, stages G3-G5) were projected to be predominantly within uACR categories A1 and A2 in 2022. Projected cumulative incidence of CKD stage transitions (disease progression) and cardio-renal complications (heart failure, myocardial infarction, stroke, and all-cause mortality) occurred mostly in uACR categories A1 and A2 between 2022 and 2027. Patients in uACR categories A1 and A2, who represent the largest proportion of patients with CKD, were projected to incur most of the health care costs associated with CKD management and cardio-renal complications for the diagnosed population (prevalence 2027). CONCLUSION: This study highlights the disproportionate population-level clinical and economic burden associated with individuals within KDIGO uACR categories A1 and A2, who represent most of the CKD population. This awareness will help health care decision makers to appropriately allocate resources and interventions to the CKD population, including those with mild to moderately increased albuminuria, to reduce clinical and economic burden associated with CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. De Nicola L, Correa-Rotter R, Navarro-González JF, et al. Projecting the Population Level Burden of CKD Progression According to Urine Albumin-to-Creatinine Ratio Categories. Kidney Int Rep. 2024. PMID: 39698359. doi:10.1016/j.ekir.2024.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。